Medical Advocates
KP1461
 
Main Page

New and Noteworthy
Journal Abstracts, Papers, and Commentaries
 



 


 
ARV Investigational  Drugs Main Page Home Page        
Last Update:  March 11, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
 
June 2012
 
Journal Papers, Abstracts, and Commentaries
 
 
Safety, Tolerability and Efficacy of KP-1461 as Monotherapy for 124 Days in Antiretroviral-Experienced, HIV-1-Infected Subjects.
Hicks C, Clay P, Redfield RR, et al
AIDS Res Hum Retroviruses. 2012 Jun 28
Abstract
 
Safety, Tolerability, and Pharmacokinetics of KP-1461 in Phase I Clinical Studies: A Single Oral Dose Study in Non-HIV-Infected Adults, and a 14-Day Dose-Escalating Study in Highly Antiretroviral-Experienced HIV-Infected Adults.
Clay PG, McRae M, Laurent JP.
 J Int Assoc Physicians AIDS Care (Chic).
 Abstract

FULL-TEXT ARTICLE
Mutation of HIV-1 Genomes in a Clinical Population Treated with the Mutagenic Nucleoside
KP1461.
 Mullins JI, Heath L, Hughes J
PLoS One. 2011 Jan 14;6(1):e15135.
Paper
 
  New kind of antiretroviral, KP-1461; clinical trial recruiting. Interview with Stephen Becker, M.D.
Becker S.
AIDS Treat News. 2007 Jul-Sep;(423):3-7.
 Abstract
 
  KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis.
Harris KS, Brabant W, Styrchak S, et al
Antiviral Res. 2005 Jul;67(1):1-9
 Abstract
   

 
Conference Reports, Abstracts,  and Posters
     
 

ARV Investigational  Drugs Main Page Home Page        

KP1461